Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Combinations of Dendritic Cells and Cytokine-induced Killer Cell （D-CIK) Immunotherapy And Anti-Programmed Death-1 In Refractory Solid Tumors

NCT02886897 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.

NCT NCT02886897
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02886897 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Combinations of Dendritic Cells and Cytokine-induced Killer Cell （D-CIK) Immunotherapy And Anti-Programmed Death-1 In Refractory Solid Tumors
Lead sponsor
Sun Yat-sen University
Phase
Phase 1/2
Overall status
Unknown status
Start date
July 31, 2016
Completion date
October 31, 2019
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer, breast cancer, colorectal cancer, hepatocellular carcinoma, non-small-cell lung cancer, renal cell carcinoma